Results 321 to 330 of about 5,029,915 (387)

Mettl3‐Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS

open access: yesAdvanced Science, EarlyView.
This study explores the roles of Mettl3‐induced N6‐methyladenosine (m6A) modifications in Focal segmental glomerulosclerosis (FSGS). The findings reveal that inhibition of Mettl3 results in podocyte injury by modulating the TJP1CDC42 pathway. Moreover, Administration of N6‐methyladenosine attenuates the FSGS phenotype in WT mice induced by Adriamycin ...
Fubin Zhu   +14 more
wiley   +1 more source

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

open access: yesAdvanced Science, EarlyView.
This study identifies a cancer‐specific interaction between CD47 and integrin αvβ3 that facilitates immune evasion. A rationally designed peptide, PSFL‐NK13, disrupts this axis, enhancing macrophage‐mediated phagocytosis and suppressing tumor growth without inducing anemia.
Peng‐Cheng Yu   +12 more
wiley   +1 more source

Revealing Causal Protein Biomarkers and Potential Therapeutic Targets for Histologic-Specific Lung Cancer. [PDF]

open access: yesJ Cell Mol Med
Sun W   +11 more
europepmc   +1 more source

Optimal D-dimer value for acute deep vein thrombosis screening in the lower limb in cases with carcinomas. [PDF]

open access: yesMedicine (Baltimore)
Kawabe K   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy